Provention Bio, Inc. (PRVB)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). The investigation concerns whether Provention and certain of its officers and/or directors have violated federal securities laws.
On April 8, 2021, Provention issued a press release "announc[ing] that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company's Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time." Following this news, Provention's stock dropped $1.73 per share, or 17.78%, to close at $8.00 on April 9, 2021.
If you are aware of any facts relating to this investigation, or purchased Provention shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.